Objectives: The objective of the present study was to assess efficiency of rehabilitation programs for patients after traumatic brain injury and acute cerebrovascular accident (stroke) in Russia. MethOds: Short-term clinical and social outcomes (health status and disability rates) of rehabilitation were analyzed in the database of the Moscow Center of Speech Pathology and Neurological Rehabilitation. Changes in the officially registered disability rates and clinical outcomes were assessed for 3 different strategies of rehabilitation: hospital, day care and home care. The decision tree model was constructed to simulate disability rates, direct and indirect costs of rehabilitation vs "no rehabilitation" scenario under conditions when officially registered disability corresponds to real health and functional status of patients. TreeAge Pro 2009 and Microsoft Excel 2010 software were used for modeling. Results: Use of officially registered disability as an endpoint does not reflect the actual effectiveness of rehabilitation programs. 90% of patients are able to live without assistance after discharge but still are registered as 1 st degree disabled (most severe degree of disability in Russia) in order to receive social benefits. According to preliminary results of modeling total cost of rehabilitation may be less than cost of "no rehabilitation" scenario if disability correlates with actual health and functional status of individuals, for example annual total cost is € 25,923 for home care rehabilitation and € 28,124 for "no rehabilitation" scenario. cOnclusiOns: It's necessary to improve approaches to official disability registration in Russia in order to make rehabilitation programs efficient. Objectives: We aimed at estimating and comparing the total management costs of patients admitted to the emergency department (ED) with recent (< 48 hours) atrial fibrillation (AF) between three types of cardioversion: direct current cardioversion (DCC), intravenous amiodarone or intravenous vernakalant. MethOds: A decision analytic model was developed to mimic the pathways of patients admitted via the ED with recent AF and to calculate an average AF management cost per strategy. The cardioversion success rates were based on published observational studies (DCC 90%, amiodarone 68%, vernakalant 70%). In case of successful conversion the patient was released directly from the ED to home (DCC 50%, amiodarone 25%, vernakalant 100%) or admitted to the hospital for a median of 1 day (DCC) or 2 days (amiodarone) reflecting cardioversion-specific times to sinus rhythm. After a failed pharmacological cardioversion, patients were assumed to receive a DCC; failed DCC was followed by intravenous amiodarone. The associated inpatient costs were retrieved from the IMS Hospital Disease Database (HDD2011). ED treatments were costed using the national health care payer tariffs. Univariate and probabilistic sensitivity analyses were performed. Results: The total AF management costs from ED to discharge were estimated at € 952 (DCC), € 1,894 (amiodarone) and € 1.354 (vernakalant). Given the relative frequencies of amiodarone (55%) and DCC (45%) to treat recent FA in Belgian ED, the weighted average management cost was € 1.470 (+ € 116/treatment vs. vernakalant). The break-even situation is reached when 75% of successfully treated vernakalant patients avoid the hospitalization (base case 100%). Based on a probabilistic sensitivity analysis, vernakalant was cost saving in 55% of the 1,000 simulations vs. current management. cOnclusiOns: In patients with recent AF, the rapid mode of action of vernakalant increases the chance of obtaining sinus rhythm within 48 hours, and its use was cost saving compared to the current average Belgian practice.
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PCV104 COst mOdEl analysis Of gORE® PROPatEn® VasCulaR gRaft VERsus standaRd EPtfE VasCulaR gRaft fOR infRaPOPlitEal byPass in PERiPhERal aRtERial disEasE (Pad) managEmEnt: sPanish sCEnaRiO
Scarpa F W. L. GORE & Associati S. r. l., Verona, Italy
Objectives: Demonstrate the cost savings of using the GORE® PROPATEN® Vascular Graft compared to standard ePTFE vascular grafts in the management of PAD patients. Superior clinical outcomes in terms of primary / secondary patency and limb salvage rates result in lower average per-patient treatment costs. Background: Vascular bypass is used in patients with PAD (Peripheral Arterial Disease) to treat ischemic rest pain, to improve walking distance in patients with severe life-limiting claudication, and to save limbs that might otherwise require amputation. When patients presenting for peripheral artery reconstruction have absent or inadequate saphenous veins due to prior use, small size, or poor quality, vascular surgeons may choose a prosthetic bypass graft. The GORE® PROPATEN® Vascular Graft features a proprietary end-point covalent linkage of heparin molecules to the luminal surface of the graft that provides sustained resistance to thrombosis. MethOds: A cost model analysis was developed to represent hospital treatment costs. A typical PAD patient's treatment pathway in Spanish clinical practice was identified by a survey involving Spanish vascular surgeons. A literature review was conducted to determine patency and limb salvage rates. Spanish GRD AP27-2012-Ministerio de Sanidad tariffs were used as hospital cost of treatment inputs. A three-year patient management cycle was considered. Results: Better patency and limb salvage rates obtained using the GORE® PROPATEN® Vascular Graft result in fewer reinterventions and amputations, corresponding to lower per-patient treatment costs. The cost model demonstrates an overall cost saving for PAD patient management using the GORE® PROPATEN® Vascular Graft for infrapopliteal bypass. The cumulative term effect of antihypertensive treatment on blood pressure was extracted from relative clinical trials and these data were extrapolated through the Hellenic SCORE and Framingham risk equations, estimating the long-term survival and qualityadjusted life-years (QALYs) gained. Costs and outcomes were evaluated over lifetime, divided into annual cycles and were discounted at 3.0% with 2014 as reference year. The analysis was conducted from the Greek third-party-payer perspective (EOPYY). Results: The total lifetime cost related to V/A/H combination was estimated to be lower (€ 10,970) compared to that of the O/A/H combination (€ 11,080), despite the higher drug acquisition cost. Moreover, the estimated QALYs gained with the V/A/H combination were 10.88 vs. 10.80 for O/A/H combination. Therefore, the V/A/H combination was found to be a dominant alternative over O/A/H combination, as it was associated with lower cost and greater efficacy. In a scenario when the ambulatory blood pressure measurements were taken into account, the ICER was far lower than the Greek GDP per capita (€ 6,845/QALY) vs. O/A/H combination, suggesting V/A/H combination to be a cost-effective choice. Extensive sensitivity analyses confirmed the robustness of the results. The probabilistic sensitivity analysis also demonstrated that there was about 80% probability for the V/A/H triple combination to be cost-effective at a willingness-to-pay threshold of € 16,000/ QALY. cOnclusiOns: This is the first study performed to compare the cost-utility of the two single-pill triple antihypertensive therapies. The V/A/H combination was proven dominant over the O/A/H combination for the treatment of moderate to severe hypertension.
Objectives: To assess cost-effectiveness of high sensitivity troponin (hs-cTn) assays for the management of adults presenting with acute chest pain at the emergency department. MethOds: An economic model was constructed to estimate lifetime costs and QALYs of five hs-cTn strategies (differing according to manufacturer, timing of the test, number of tests and cutoff point for a positive test result) compared to standard troponin (sTn) testing at presentation and at 10-12 hours, which was considered the reference standard. In the base case, it was assumed that sTn testing had perfect accuracy for diagnosing AMI and only patients with a positive test for sTn were at increased risk for adverse events and would benefit from immediate treatment. In a secondary analysis, a proportion of patients with a positive hs-cTn test and a negative sTn test were at increased risk for adverse events and would benefit from immediate treatment. Results: Base case: Strategies considered cost-effective depending upon ICER thresholds were Abbott ARCHITECT hs-cTnI 99th centile (thresholds < £6,597), Beckman Coulter hs-cTnI 99th centile (thresholds £6,597 -£30,042), Abbott ARCHITECT hscTnI optimal strategy (thresholds £30,042 -£103,194) , and the sTn test (thresholds > £103,194) . Secondary analysis: Strategies considered cost-effective were Abbott ARCHITECT hs-cTnI 99th centile (< £12,217), Roche Elecsys hs-cTnT 99th centile (£12,217 -£14,992) and Abbott ARCHITECT hs-cTnI optimal strategy (> £14,992). STn was dominated. Sensitivity/subgroup analyses: Main drivers are: the difference in outcomes between treated and untreated patients, and treatment costs for patients testing false-positive. Hs-cTn testing is more cost-effective in younger age, pre-existing coronary artery disease, and symptom onset < 3hrs ago. No testing is only cost-effective when pre-test prevalence is 1%. cOnclusiOns: There is no strong evidence to prefer one hs-cTn testing strategy over another. Results do indicate that hs-cTn testing in general may be cost-effective compared to sTn testing, especially in the secondary analysis. Objectives: Recent studies have demonstrated the safety and efficacy of catheter-based renal denervation (RDN) for the treatment of resistant hypertension. These studies have been used to estimate the cost effectiveness of this approach, however, there is no such published estimation in the Dutch health care setting. We aimed to determine the cost effectiveness of RDN from the perspective of the health care payer in The Netherlands. MethOds: A Markov state-transition model previously constructed in TreeAge ® was adapted to Microsoft Excel ® . The Excel-based model was updated with costs and quality-adjusted life years (QALYs) relevant to the Dutch setting and the cost effectiveness of RDN was compared with standard of care (SoC) for patients with resistant hypertension. The efficacy of RDN treatment was modelled as a reduction in the risk of cardiovascular events associated with a lower systolic blood pressure (SBP). Results: Base case deterministic results showed that treatment with RDN resulted in an increase in QALYs of 0.89 at an incremental cost of € 1,315 per patient resulting in an ICER of just € 1,474 Deterministic and probabilistic sensitivity analyses (PSA) indicated treatment with RDN therapy was cost effective at conventional willingness-topay thresholds used in The Netherlands of € 10,000-80,000 per QALY. Furthermore, 9.5% of PSA iterations showed RDN to be a cost saving treatment compared to SoC. cOnclusiOns: RDN is a cost-effective intervention for patients with resistant hypertension in The Netherlands.
PCV101 COst EffECtiVEnEss Of REnal dEnERVatiOn thERaPy fOR thE tREatmEnt Of REsistant hyPERtEnsiOn in thE nEthERlands
